Research programme: malononitrilamide compounds - Sanofi-Aventis/Astellas Pharma

Drug Profile

Research programme: malononitrilamide compounds - Sanofi-Aventis/Astellas Pharma

Alternative Names: Malononitrilamide compounds research programme - Sanofi-Aventis/Fujisawa

Latest Information Update: 18 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Nitriles
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Transplant rejection

Most Recent Events

  • 30 Jun 2006 Discontinued - Preclinical for Transplant rejection in Europe (unspecified route)
  • 30 Jun 2006 Discontinued - Preclinical for Transplant rejection in USA (unspecified route)
  • 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top